NASDAQ:DBVT DBV Technologies (DBVT) Stock Price, News & Analysis $10.30 -0.19 (-1.81%) Closing price 04:00 PM EasternExtended Trading$10.30 0.00 (0.00%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About DBV Technologies Stock (NASDAQ:DBVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DBV Technologies alerts:Sign Up Key Stats Today's Range$9.50▼$10.5350-Day Range$7.74▼$11.4852-Week Range$2.20▼$12.78Volume61,663 shsAverage Volume190,373 shsMarket Capitalization$282.12 millionP/E RatioN/ADividend YieldN/APrice Target$14.75Consensus RatingModerate Buy Company Overview DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. Read More DBV Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreDBVT MarketRank™: DBV Technologies scored higher than 75% of companies evaluated by MarketBeat, and ranked 272nd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDBV Technologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DBV Technologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($7.05) to ($5.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 7.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DBV Technologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.08% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.08% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.89 News SentimentDBV Technologies has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for DBV Technologies this week, compared to 2 articles on an average week.Search Interest3 people have searched for DBVT on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $730.00 in company stock.Percentage Held by InsidersOnly 1.44% of the stock of DBV Technologies is held by insiders.Percentage Held by Institutions71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DBV Technologies' insider trading history. Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DBVT Stock News HeadlinesDBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 2 at 3:31 AM | americanbankingnews.comAnalysts Issue Forecasts for DBVT Q2 EarningsJuly 1 at 2:39 AM | americanbankingnews.comGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.July 2 at 2:00 AM | Weiss Ratings (Ad)DBV Technologies (NASDAQ:DBVT) Upgraded at Lifesci CapitalJune 29 at 3:35 AM | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Given Market Outperform Rating at JMP SecuritiesJune 27, 2025 | americanbankingnews.comDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old - MorningstarJune 26, 2025 | morningstar.comMDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years OldJune 26, 2025 | uk.finance.yahoo.comDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years OldJune 25, 2025 | globenewswire.comSee More Headlines DBVT Stock Analysis - Frequently Asked Questions How have DBVT shares performed this year? DBV Technologies' stock was trading at $3.09 on January 1st, 2025. Since then, DBVT stock has increased by 233.3% and is now trading at $10.30. View the best growth stocks for 2025 here. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) released its earnings results on Friday, April, 11th. The company reported ($1.10) EPS for the quarter. The company earned $0.51 million during the quarter. DBV Technologies had a negative net margin of 3,249.99% and a negative trailing twelve-month return on equity of 278.24%. When did DBV Technologies' stock split? DBV Technologies's stock reverse split before market open on Friday, November 29th 2024.The 1-5 reverse split was announced on Monday, November 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Meta Platforms (META), Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings4/11/2025Today7/02/2025Next Earnings (Estimated)7/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DBVT CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$14.75 High Stock Price Target$21.00 Low Stock Price Target$7.25 Potential Upside/Downside+43.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($4.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$113.92 million Net Margins-3,249.99% Pretax Margin-3,249.79% Return on Equity-278.24% Return on Assets-140.54% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual Sales$4.15 million Price / Sales67.98 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book7.25Miscellaneous Outstanding Shares27,390,000Free Float26,996,000Market Cap$282.12 million OptionableOptionable Beta-0.59 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:DBVT) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.